http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-1790331-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a1c8ec1f1e7a71351775e7986f8ffae6 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0053 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-675 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-08 |
| filingDate | 2006-03-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6d15b40c327944bd06f6716077e74030 |
| publicationDate | 2007-05-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | EP-1790331-A1 |
| titleOfInvention | Use of pyridoxal-5-phosphate for the treatment of cardiovascular and related pathologies |
| abstract | Compositions and methods for treatment and prevention of hypertrophy, congestive heart failure, ischemic heart disease, organ ischemia, tissue ischemia, acute coronary syndrome, unstable angina, ischemia-related conditions, such as ischemia reperfusion injury and cellular dysfunction, are described. Methods are directed to administering pharmaceutical compositions containing at least one compound selected from pyridoxal-5'-phosphate, pyridoxine, pyridoxal, and pyridoxamine, in (1) an oral dosage of 100-1000 mg per day, for example, 200-300 mg/day, 250 mg/day or 750 mg/day or (2) a parenteral dosage of 1.88 to 18.76 mg/day, for example, 3.76 to 5.64 mg/day, 4.69 mg/day, or 14.07 mg/day. Methods are also suitable for preventing these conditions after a traumatic event, such as invasive heart surgery. |
| priorityDate | 2005-11-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 92.